RT Journal Article
SR Electronic
T1 Early super-spreader events are a likely determinant of novel SARS-CoV-2 variant predominance
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.23.21254185
DO 10.1101/2021.03.23.21254185
A1 Ashish Goyal
A1 Daniel Reeves
A1 Joshua T. Schiffer
YR 2021
UL http://medrxiv.org/content/early/2021/03/24/2021.03.23.21254185.abstract
AB The emergence of multiple new SARS-CoV-2 variants, characterized to varying degrees by increased infectivity, higher virulence and evasion of vaccine and infection-induced immunologic memory, has hampered international efforts to contain the virus. While it is generally believed that these variants first develop in single individuals with poor immunologic control of the virus, the factors governing variant predominance in the population remain poorly characterized. Here we present a mathematical framework for variant emergence accounting for the highly variable number of people secondarily infected by individuals with SARS-CoV-2 infection. Our simulations suggest that threatening new variants probably develop within infected people fairly commonly, but that most die out and do not achieve permanence in the population. Variants that predominate are more likely to be associated with higher infectiousness, but also the occurrence of a super-spreader event soon after introduction into the population.Competing Interest StatementThe authors have declared no competing interest.Funding StatementJTS received supplemental COVID funding via National Institute of Allergy and Infectious Diseases (R01 AI121129-05S1) and the Council of State and Territorial EpidemiologistsAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NAAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll code is available upon request.